Plain-English translation of NCT06106906 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CD19 CAR-T cell therapy, a personalized treatment that uses your own immune cells to help control lupus. Researchers want to see if this medication is safe and whether it can help people with active lupus whose disease hasn't improved with standard treatments like steroids and immunosuppressive drugs.
Many people with lupus continue to struggle even after trying standard medications, and some become dependent on high doses of steroids, which can cause serious side effects like diabetes, bone damage, and infections. This trial exists because there is a real need for more effective treatment options for people whose lupus remains active despite current therapies.
You likely qualify if…
You likely don't qualify if…
You would receive one intravenous infusion of the cell therapy at the hospital, followed by follow-up visits over the next 2 years to monitor how well the treatment works and check for any side effects. The study will track your lupus activity, measure changes in your symptoms, and assess whether you're able to reduce your steroid doses. You'll need to be willing and able to attend all scheduled visits and follow the study requirements for the full 2-year period.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Guangzhou Bio-gene Technology Co., Ltd
Enrollment target
~15 participants
Started
June 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qiubai Li, Professor
Department of Rheumatology and Immunology, Wuhan Union Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.